hepatocellular carcinoma

Bristol-Myers Squibb Company has announced the Phase III BRISK-FL trial results of investigational agent brivanib versus sorafenib as a first-line treatment in patients with advanced hepatocellular carcinoma (HCC).

The randomised, double-blind study conducted in patients with advanced HCC who have not received prior systemic treatment, failed to meet its primary overall survival objective based on a non-inferiority statistical design.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Bristol-Myers Squibb global development and medical affairs senior vice president Brian Daniels said that the treatment options for patients with advanced hepatocellular carcinoma were limited, and the company was disappointed that the primary endpoint was not met.

"Bristol-Myers Squibb remains committed to developing medicines for the treatment of diseases with serious unmet medical need, including diseases of the liver such as hepatitis C, hepatitis B, and liver cancer."

"Bristol-Myers Squibb remains committed to developing medicines for the treatment of diseases with serious unmet medical need, including diseases of the liver such as hepatitis C, hepatitis B, and liver cancer," Daniels added.

Bristol-Myers Squibb is considering options for the ongoing brivanib development programme and will continue with ongoing clinical trials of brivanib, which include hepatocellular carcinoma and other tumor types.

See Also:

Additionally, the company shared the BRISK-FL results with the clinical trial investigators and is considering working with the investigators regarding the ongoing management of patients receiving the study drug.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Brivanib is an investigational, oral, anti-tumourigenic, which inhibits vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptors (FGFR).

Image: Gross specimen of the liver showing hepatocellular carcinoma. Photo: courtesy of Netha Hussain.